Clinical Trial Update: A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma [NA]

View source ↗

Summary

A prospective registry study evaluating stereotactic ablative radiotherapy (SABR) for oligometastatic renal cell carcinoma, currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Renal Cell Carcinoma, RCC | NA | Status: NOT_YET_RECRUITING